Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines
Abstract Background Previous studies showed that the combination of an anti-Epidermal growth factor (EGFR) and a MEK-inhibitor is able to prevent the onset of resistance to anti-EGFR monoclonal antibodies in KRAS-wild type colorectal cancer (CRC), while the same combination reverts anti-EGFR primary...
Main Authors: | Pietro Paolo Vitiello, Claudia Cardone, Giulia Martini, Davide Ciardiello, Valentina Belli, Nunzia Matrone, Giusi Barra, Stefania Napolitano, Carmina Della Corte, Mimmo Turano, Maria Furia, Teresa Troiani, Floriana Morgillo, Ferdinando De Vita, Fortunato Ciardiello, Erika Martinelli |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-01-01
|
Series: | Journal of Experimental & Clinical Cancer Research |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13046-019-1035-0 |
Similar Items
-
Treatment of Cutaneous Melanoma Harboring SMO p.Gln216Arg Mutation with Imiquimod: An Old Drug with New Results
by: Teresa Troiani, et al.
Published: (2021-03-01) -
Antitumor activity of sorafenib in human cancer cell lines with acquired resistance to EGFR and VEGFR tyrosine kinase inhibitors.
by: Floriana Morgillo, et al.
Published: (2011-01-01) -
Targeting EphA2 and DDR signaling can overcome the BRAF and MEK inhibitors acquired resistance in melanoma cell lines
by: Valentina Belli, et al.
Published: (2023-02-01) -
Combined blockade of MEK and PI3KCA as an effective antitumor strategy in HER2 gene amplified human colorectal cancer models
by: Valentina Belli, et al.
Published: (2019-06-01) -
Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer
by: Pietro Paolo Vitiello, et al.
Published: (2021-01-01)